Top 10 pharmaceutical companies by revenues in 2026 | Official Figures | iPharmaCenter

Sl No	Brand	Q1	H1	9M	Total
1	Johnson and Johnson	$24.0
2	Eli Lilly	$19.8
3	Roche	$18.8
4	AstraZeneca	$15.3
5	Novo Nordisk	$15.2
6	AbbVie	$15.0
7	Pfizer	$14.4
8	Merck	$14.3
9	Novartis	$13.1
10	Sanofi	$12.4

Top pharmaceutical companies by revenues | 2026

1. JOHNSON AND JOHNSON

   Q1 REVENUES:

   In the first quarter of 2026, the company reported total sales of $24.1 billion, reflecting a 9.9% increase. Revenue from Innovative Medicines reached $15.4 billion.

   Global operational sales in the Innovative Medicines segment rose by 7.4%. This growth was mainly supported by strong performance from Darzalex, Carvykti, Erleada, and Rybrevant/Lazcluze in oncology, Tremfya in immunology, and Spravato in neuroscience.

   
   

   Also read: Foundayo (orforglipron) Wins FDA Approval as First Anytime GLP‑1 Tablet for Weight Loss

   
   

2. ELI LILLY

   Q1 REVENUES:

   Revenue in the first quarter of 2026 rose by 56% to $19.8 billion, largely driven by higher volumes, with some offset from lower realized prices for Mounjaro and Zepbound.

   Combined revenue from Ebglyss, Inluriyo, Jaypirca, Kisunla, Mounjaro, Omvoh, and Zepbound reached $13.4 billion, supported mainly by strong demand for Mounjaro and Zepbound.

   Additionally, key products across the immunology, oncology, and neuroscience segments recorded a 160% increase in revenue.

   
   

3. ROCHE

   Q1 REVENUES:

   Roche reported group sales growth of 6% at constant exchange rates (CER), while sales declined 5% in Swiss francs (CHF) and increased 9% in U.S. dollars. The Pharmaceuticals Division posted a 7% rise in sales at CER, with a 4% decline in CHF terms and a 10% increase in USD.

   
   

   This performance was driven by sustained demand for therapies targeting serious conditions, particularly Xolair (chronic hives, food allergies), Phesgo (breast cancer), Hemlibra (haemophilia A), Vabysmo (severe eye diseases), and Ocrevus (multiple sclerosis).

   
   

4. ASTRAZENECA

   Q1 REVENUES

   Total revenue reached $15.3 billion, marking an 8% increase to $15,288 million, supported by double-digit growth in the oncology and rare disease segments.

   Key contributors to this performance included Tagrisso, Imfinzi, and Farxiga.

   
   

   Also read: New Hope for GVHD Patients as Rezurock Wins EU Approval

   
   

5. NOVO NORDISK

   Q1 REVENUES:

   Novo Nordisk reported net sales of DKK 96,823 million, reflecting continued momentum in its GLP-1 portfolio. The U.S. launch of the Wegovy pill on January 5, 2026, has shown rapid uptake, with weekly prescriptions surpassing 200,000 by mid-April.

   Total prescriptions reached approximately 1.3 million in Q1 2026 and have exceeded 2 million since launch, positioning the product as the strongest GLP-1 launch by volume in the U.S. to date.

   
   

6. ABBVIE

   Q1 REVENUES

   AbbVie reported first-quarter worldwide net revenues of $15.0 billion, representing growth of 12.4% on a reported basis and 10.3% on an operational basis.

   Skyrizi generated global net revenues of $4.5 billion, rising 30.9% as reported and 29.2% operationally.

   Rinvoq recorded global net revenues of $2.1 billion, reflecting an increase of 23.3% on a reported basis and 20.2% on an operational basis.

   
   

7. PFIZER

   Q1 REVENUES

   Pfizer reported first-quarter 2026 revenues of $14.5 billion, up $736 million, or 5%, compared with the same period last year.

   The operational growth was mainly supported by higher sales of Padcev, Eliquis, oncology biosimilars, Nurtec, and several other products, partially offset by a decline in COVID-19–related revenues.

   
   

   Also read: Johnson and Johnson approved Tecvayli plus Darzalex Faspro for 2L multiple myeloma

   
   

8. MERCK

   Q1 REVENUES

   Merck reported pharmaceutical revenues of $14.3 billion, with Keytruda contributing $8.0 billion.

   The growth was largely fueled by increased global demand in metastatic settings, particularly in urothelial cancer, along with strong adoption in earlier-stage treatments such as triple-negative breast cancer, cervical cancer, and renal cell carcinoma (RCC).

   
   

9. NOVARTIS

   Q1 REVENUES

   Net sales totaled $13.1 billion, reflecting a decline of 1% (down 5% at constant currencies). Volume growth contributed 13 percentage points, but this was more than offset by a 14-percentage-point impact from generic competition.

   
   

   Among top-performing products, Cosentyx generated $1.6 billion in revenue, while Kisqali recorded $1.5 billion.

   
   

10. SANOFI

    Q1 REVENUES

    Sanofi reported first-quarter revenues of €10.5 billion. Sales from recently launched pharmaceutical products rose 49.6% to €1.2 billion, supported mainly by Ayvakit, Altuviiio, and Sarclisa.

    
    

    Dupixent generated €4.2 billion in sales, reflecting a 30.8% increase and a strong opening to 2026.